The impact of the overall radiotherapy time on clinical outcome of patients with nasopharyngeal carcinoma

a retrospective study

Stoker, S.D.; Fles, R.; Herdini, C.; Rijntjes, F.J.F.; Tjokronagoro, M.; Dwidanarti, S.R.; Sikorska, K.; Leemans, C.R.; Schmidt, M.K.; Al-Mamgani, A.; Wildeman, A.; Haryana, S.M.; Indrasari, S.R.; Tan, I.B.

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0151899

Link to publication

Creative Commons License (see https://creativecommons.org/use-remix/cc-licenses):
CC BY

Citation for published version (APA):
Stoker, S. D., Fles, R., Herdini, C., Rijntjes, F. J. F., Tjokronagoro, M., Dwidanarti, S. R., ... Tan, I. B. (2016). The impact of the overall radiotherapy time on clinical outcome of patients with nasopharyngeal carcinoma: a retrospective study. PLoS ONE, 11(3), [e0151899]. https://doi.org/10.1371/journal.pone.0151899

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
The Impact of the Overall Radiotherapy Time on Clinical Outcome of Patients with Nasopharyngeal Carcinoma; A Retrospective Study

S. D. Stoker1,2, R. Fles1, C. Herdini3, F. J. F. Rijntjes1, M. Tjokronagoro4†, S. R. Dwidanarti4, K. Sikorska5, C. R. Leemans2, M. K. Schmidt6,7, A. Al-Mamgani8, M. A. Wildeman1,9, S. M. Haryana10, S. R. Indrasari3, I. B. Tan1,3,11*  
1 Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, 2 Department of Otolaryngology—Head and Neck Surgery, VU University Medical Centre, Amsterdam, The Netherlands, 3 Department of Otolaryngology—Head and Neck Surgery, Gadjah Mada University, Dr. Sardjito hospital, Yogyakarta, Indonesia, 4 Department of Radiotherapy, Gadjah Mada University, Dr. Sardjito hospital, Yogyakarta, Indonesia, 5 Department of Bioinformatics, The Netherlands Cancer Institute, Amsterdam, The Netherlands, 6 Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands, 7 Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands, 8 Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands, 9 Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands, 10 Department of Histology, Cell and Tumour Biology, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia, 11 Department of Oral and Maxillofacial Surgery, Academic medical Centre, Amsterdam, The Netherlands

† Deceased.  
* i.tan@nki.nl

Abstract

Purpose

In Yogyakarta, nasopharyngeal carcinoma (NPC) shows a poor response to radiotherapy treatment. Previous study showed a prolonged overall treatment time (OTT), due to interruptions during treatment. This study explores the association between clinical outcome and OTT. Secondary, the relation between clinical outcome and disease stage, waiting time to radiation (WT) and chemotherapy schedule was explored.

Methods

In this retrospective cohort, 142 patients who started curative intent radiotherapy for NPC between March 2009 and May 2014, with or without chemotherapy, were included. The median follow up time was 1.9 years. Data was collected on WT, OTT, disease stage, and chemotherapy schedule. Time factors were log-transformed. Clinical outcome was defined as therapy response, loco-regional control (LRC), disease free survival (DFS) and overall survival (OS).

Results

The median WT was 117 days (range 12–581) and OTT was 58 days (43–142). OTT and disease stage were not associated to any of the clinical outcome parameters. The log-WT
Conclusion

Not receiving concurrent chemotherapy showed the strongest risk for poor outcome. Since the choice of chemotherapy is related to a variety of factors, like the WT and patient’s physical condition when radiation can start, careful interpretation is needed. Reason for not finding a relation between OTT and clinical outcome might be the low number of patients who finished radiotherapy within 7 weeks, or by a stronger detrimental effect of other factors.

Introduction

Nasopharyngeal cancer (NPC) is the most common malignancy in the head and neck region in Indonesia [1]. The incidence is estimated at 6:100,000, which is probably an underestimation since many patients living in the rural areas might stay undiagnosed [2]. In literature, 3-year overall survival for NPC are reported as 70 to 80%, or even higher. Studies in Indonesia showed a 3-year overall survival of only 30% [3, 4]. Most of the studies with the high survival rates are derived from clinics with advanced and readily available treatment facilities. More than 85% of the NPC patients are diagnosed in low- and middle-income countries, with less advanced equipment and limited capacity [2, 5]. Therefore, actual NPC survival will be much lower than reported in literature and more likely to be in the range of Yogyakarta. This study aims to identify factors associated with poor clinical outcome.

The best treatment for advanced NPC is radiotherapy in combination with chemotherapy, 60–70 Gray (Gy) to the nasopharynx and neck metastases and an elective dose of 40–50 Gy to the uninvolved parts of the neck [3, 6]. For stage I (AJCC 6th edition), radiotherapy alone gives satisfactory results [7–9]. General consensus for radiotherapy is that treatment should be given without interruptions. When treatment is interrupted repopulation of tumour cells can occur, which is believed to be a significant risk for treatment failure [10–13]. This phenomenon has been proven in both xenograft animal models and clinical studies with cervical cancer, bladder cancer and head and neck cancer [13–19]. One of the largest studies in head and neck cancer concerning the effect of overall radiotherapy treatment time (OTT) on clinical outcome is from the Danish group [20]. They proved the benefit of 6 fractions a week above 5 fractions per week. Unfortunately, NPC was excluded.

It is assumable that treatment interruption during radiotherapy in NPC will also negatively affect clinical outcome, but multiple, large studies confirming this, are lacking. Besides, controversial results are found [17, 21–27]. One of the most recently published studies is from Li et al. [27]. They included 321 patients treated with radiotherapy for NPC, but they couldn’t proof the negative effect of a long OTT on local-regional control and distant metastases free survival (Li 2015). Another way to shorten OTT is by using accelerated radiation schemes. However, also in these studies conflicting results are shown with regard to the impact on outcome [24, 25–26]. Pan et al. found improved loco-regional control (LRC) and overall survival (OS) [25], but Lee et al. and Theo et al. only showed more side effects without improved clinical outcome [24, 26].

Previous study in Yogyakarta showed a mean number of missed days of 10 per patient. Meaning that to complete the full course of treatment, the OTT was prolonged by two weeks,
since radiotherapy is only given on weekdays [28]. In the discussion was hypothesized that the interruptions during radiotherapy, and thus the length of the OTT, could have influenced clinical outcome to a great extent. Therefore, the aim of the current study is to explore the association between OTT and clinical outcome in NPC. If these results show a significant disadvantage in clinical outcome when the OTT is longer, a first step is made in finding solutions for the problem of the poor prognosis of patients with NPC. Since, the OTT can be shortened if effort is made [28]. It is likely that clinical outcome is also related to disease stage, waiting time to start radiotherapy (WT), and the chemotherapeutic schedule (neo-adjuvant and/or concurrent), therefore these factors were also taken in analysis.

The preferred treatment of choice for NPC in this institute is concurrent chemoradiotherapy. For many patients it was not exceptional that the waiting time for radiotherapy exceeded 3 months. To prevent disease progression in this period, neo-adjuvant chemotherapy was given. In some patients the physical condition was deteriorated to such extend that another course of chemotherapy was not an option anymore, so they received radiation without chemotherapy.

Method

Study design and eligibility

This retrospective study was conducted in Dr. Sardjito hospital, Gadjah Mada University, in Yogyakarta, Indonesia. Ethical approval was obtained from this institution’s review board.

Data was obtained from the hospital’s medical records and the online data-management system introduced in 2008 [29]. Patient information was anonymized and de-identified before analysis. Patients were deemed eligible when they started curative intent radiotherapy, with or without chemotherapy, for histologically confirmed NPC (World Health Organization type 1, 2 or 3). There is an overlap of patients with the studies published in 2013 and 2014 [4, 28]. There were no medical intervention in these or the current study, therefore no separate analysis was performed.

Between March 2009 and May 2014, 193 patients started radiotherapy for NPC. Fifty-one patients (26%) were excluded. Reasons for exclusion were; drop out during radiotherapy (due to side effects (n = 12), death (n = 5), financial problems (n = 4) or unknown reason (n = 8)), suspect distant metastasis (n = 9), unreliable staging (n = 7), second primary (n = 1), or a short (<3 months) post-treatment follow up period (n = 5). Subsequently, 142 patients were included for study outcome analysis. Staging at diagnosis was performed by computed tomography (CT) scan of the head and neck, ultrasound of the abdomen, X-ray of the thorax and a bone survey, and scored according to the 6th edition of the American Joint Committee on Cancer (UICC/AJCC).

Treatment

All patients were treated with external beam radiotherapy, 2 dimensional or 3 dimensional, in fractions of 2 Gy per day, 5 times a week (not in the weekends). The protocol for NPC was 60 Gy for T1 disease and 66–70 Gy for T2-4 to the nasopharynx; and 40–46 Gy for N0-1 and 50 Gy for N2-3 to the whole neck (including the supraclavicular fossa). Persistent nodes were radiated up to 66–70 Gy. The overall treatment time (OTT), starting from the first day of radiotherapy until the last day of radiotherapy, could be finished within 42–47 days. The waiting time to radiotherapy (WT) is calculated from the day of diagnosis until start radiotherapy.

Different schedules for chemotherapy were used. The schedule depended on the patient’s physical status, type of insurance, availability of the drugs and waiting time for radiotherapy at that time. When the waiting time to radiotherapy was long (in particular in case of poor patients), neo-adjuvant chemotherapy was given to prevent progression. Concurrent
chemotherapy was the preferred choice, but physical deterioration made this schedule not possible for all patients. Neo-adjuvant chemotherapy consisted of; cisplatin, carboplatin, fluorouracil, capecitabine, docetaxel, or paclitaxel. Concurrent chemotherapy regimens consisted of weekly cisplatin or carboplatin. Patients were categorized into 4 groups; concurrent, concurrent and neo-adjuvant, neo-adjuvant or no neo-adjuvant or concurrent chemotherapy. In five cases, adjuvant chemotherapy was given. Adjuvant chemotherapy consisted of carboplatin, paclitaxel and/or capecitabine. Adjuvant chemotherapy was ignored for group categorization.

**Clinical outcome**

Clinical outcome was measured by 4 parameters, i.e.; therapy response, local-regional control (LRC), disease free survival (DFS) and overall survival (OS).

**Therapy response.** Post-treatment protocol for treatment response was endoscopy, biopsy of the primary local tumour site, CT-scan of the head and neck area, ultra-sound of the abdomen, x-ray of the thorax and a bone survey. Unfortunately, not all patients completed this protocol. Therapy response was set as complete response or incomplete response. In case of uncertainty about therapy response, patients were excluded for therapy response analysis. Complete response was defined as; 1) all imaging studies, including biopsy showed no disease, and there was no recurrent disease within 6 months or, 2) in case of clinical examination only (including endoscopy), and there was no suspicion for disease, and no suspicion of recurrent disease in the following 2 years. Incomplete response was defined as; 1) local or regional disease confirmed by biopsy, or cytology within 6 months post-treatment or, 2) a suspect CT scan for loco-regional residual disease and died within 1 year or, 3) distant metastases within 6 months after radiotherapy, confirmed by progression during follow up. Exclusion criteria for therapy response analysis were 1) no clinical follow up in the first 6 months or, 2) suspected incomplete response (never confirmed by biopsy or progression during follow-up), but alive without complaints for at least 2 years.

**Local-regional control.** LRC was defined as the time between the last day of radiotherapy till the date of local and/or regional disease. In case of persistent disease, the date of event was set at 3 days post-treatment. Patients were censored if they were alive without local-regional disease. In case of uncertainty about the local-regional status they were excluded for this analysis.

**Disease free survival.** DFS was defined as the time between the last day of radiation till the date of recurrent disease (local, regional or distant) or the date of death. In case of persistent disease, the date of event was set at 3 days post-treatment. Patients who had no evidence of disease at last follow-up were censored at the date of last contact.

**Overall survival.** OS was defined as the time between start date of radiotherapy till the date of death. A different starting point was chosen, since the length of OTT time differed considerably, which would affect OS. Patients who were alive at last follow up were censored. Patients who died due to a second primary tumour were excluded from this analysis.

**Statistical analysis**

The main interest was to relate OTT and WT to therapy response, LRC, DFS and OS. These time-related predictors (OTT and waiting time) were skewed to the right, and therefore transformed into (normal) log scale. Log-transformed OTT and WT were analyzed in univariable logistic regression and Cox models. Shapes of the relationships for the time to event outcomes were evaluated using martingale residuals plots. In the multivariable models we included WT, OTT as well as chemotherapy treatment schedule and tumor stage as possible confounders. For the time to event outcomes an independence test based on log rank statistics was used to
find a cut-off, which separates best patients with good and poor prognosis. The analyses were performed using SPSS software (version 22) and R software (version 3.1.0). P-values $< 0.05$ were considered statistically significant.

**Results**

**Patients & treatment description**

From the 142 patients, 97 (68%) were male. The histological type of NPC was WHO 3 in 94% of the cases. At diagnosis, 84% had late stage disease. Chemotherapy was administered in 90% of the patients (Table 1). For 6 (4%) patients there was ambiguity about the actual given chemotherapy. The median WT was 117 days (range 12–581). The median dosage was 66 Gy (range 60–76). The median OTT was 58 days (range 43–142). The median follow up time was 708 days (1.9 years) (calculated from the start of radiotherapy).

**Association between OTT and outcome**

**Therapy response.** Therapy response was available for 120 patients, 60 patients had a complete response. Disease stage was not associated to response. Patients with a complete response had an equal median OTT as patients with an incomplete response, 58 days (Table 2). The median WT was 101 versus 140 days for patients with a complete or incomplete response, respectively (Kruskal-Wallis $p < 0.01$) (Table 2). Also in the univariable analyses, wherein time parameters were transformed into a (normal) log scale, significant odds ratios for poor therapy outcome were found for log WT, and not for log OTT (Table 3). A plot summary was made to visualize the clinical interpretation of the increased risk when the WT is increased (Fig 1).

| Tumour stage | Patients | Chemotherapy schedule |
|--------------|----------|-----------------------|
|              | AJCC     | Conc | Conc & adj | Conc & neo | Neo | Neo & adj | Adj | No chemo | Missing |
| I            | 3 (2.1)  | 0    | 0           | 0           | 0   | 0         | 1   | 2         |
| IIa          | 1 (0.7)  | 0    | 0           | 0           | 1   | 0         | 0   | 0         |
| IIb          | 16 (13)  | 6    | 0           | 2           | 5   | 1         | 0   | 4         | 1       |
| III          | 50 (35)  | 19   | 0           | 6           | 23  | 0         | 0   | 1         | 1       |
| IVa          | 20 (14)  | 6    | 0           | 0           | 11  | 0         | 2   | 0         | 1       |
| IVb          | 49 (35)  | 9    | 1           | 6           | 29  | 0         | 1   | 2         | 1       |
| Total (%)    | 142 (100)| 40 (28)| 1 (0.7)    | 14 (10)     | 69 (49)| 1 (0.7)  | 3 (2.1)| 8 (5.6)  | 6 (4)   |

AJCC = American joint Committee for Cancer 6th edition; conc = concurrent chemotherapy; neo = neo-adjuvant chemotherapy; adj = adjuvant chemotherapy

doi:10.1371/journal.pone.0151899.t001

| Tumour stage | Patients | Chemotherapy schedule |
|--------------|----------|-----------------------|
|              | Conc     | Conc & adj | Conc & neo | Neo | Neo & adj | Adj | No chemo | Missing |
| I            | 3 (2.1)  | 0           | 0           | 0   | 0         | 1   | 2         |
| IIa          | 1 (0.7)  | 0           | 0           | 1   | 0         | 0   | 0         |
| IIb          | 16 (13)  | 6           | 0           | 2   | 5         | 1   | 4         | 1       |
| III          | 50 (35)  | 19          | 0           | 6   | 23        | 0   | 1         | 1       |
| IVa          | 20 (14)  | 6           | 0           | 0   | 11        | 2   | 0         | 1       |
| IVb          | 49 (35)  | 9           | 1           | 6   | 29        | 0   | 2         | 1       |
| Total (%)    | 142 (100)| 40 (28)    | 1 (0.7)    | 14 (10) | 69 (49) | 1 (0.7) | 3 (2.1) | 8 (5.6) | 6 (4) |

Table 1. Tumour stage at diagnosis & treatment.

Table 2. OTT & WT and complete or incomplete therapy response.

| Total | Complete response | Incomplete response |
|-------|-------------------|---------------------|
|       | OTT Days (range)  | Days                |
| Median OTT | 58 (43–142) | 58 | 58 | p = 0.26 |
| Median WT  | 117 (12–581)    | 101                  | 140 | p = 0.01* |

OTT = overall radiation treatment time; WT = waiting time to radiotherapy

*significant outcome

doi:10.1371/journal.pone.0151899.t002
the multivariable analysis for therapy response, only chemotherapy schedule remained significant (Table 4).

**Local regional control.** For LRC analysis, 81 patients were available, 43 events occurred. The 2-year LRC was 48% (median 1.77 years) (Fig 2A). Univariable Cox model showed a significant HR for poor LRC when the log WT was increased. Based on the exploratory analysis the association of log OTT and LRC was not linear. The optimal cut-off point was selected for 72 days, however this was statistically not significant (log rank p-value 0.49) (Table 3). A significant optimal cut-off point for the WT, which separates good and poor LRC, was found at 130 days (Fig 3A, log rank p<0.001). In the multivariable Cox-model only chemotherapy remained significant (Table 4, Fig 4A).

**Disease free survival.** For DFS analysis, 124 patients were available, 86 events occurred. The 2-year DFS was 32% (median 0.94 years) (Fig 2B). Univariable Cox model showed a significant HR for poor DFS when the log WT was increased. Log OTT was not significantly

---

**Table 3. Univariable logistic regression (therapy response), and Cox model (LRC, DFS and OS).**

| Therapy response |  
|------------------|------------------|------------------|
| OR   | P-value | OR   | P-value | OR   | P-value | OR   | P-value |
| Log OTT | 2.3 | 0.37 | 1.4 | 0.49 | 1.2 | 0.73 | 2.0 | 0.21 |
| Log WT  | 1.7 | 0.02* | 1.7 | 0.01* | 1.4 | 0.01* | 1.3 | 0.09 |

OR = odds ratio; HR = hazard ratio; LRC = loco-regional control; DFS = disease free survival; OS = overall survival; OTT = overall radiation treatment time; WT = waiting time to radiotherapy

1 = based on a cut-off point of 72 days

*significant outcome

doi:10.1371/journal.pone.0151899.t003

---

**Fig 1. Probability of incomplete response as function of the waiting time (WT).** Probability of 0 is a complete response and 1.0 an incomplete response. The WT is shown as transformed back into a continuous scale. In the first 3 months, the increase of probability of incomplete response is steeper than when the length of WT is longer. The probability on incomplete response seems to reach a plateau level.

doi:10.1371/journal.pone.0151899.g001
associated to DFS (Table 3). A significant optimal cut-off point for the WT, which separates good and poor DFS, was found at 130 days (Fig 3B, log rank \(p < 0.001\)). In the multivariable Cox-model only chemotherapy schedule remained significant; patients who only received neo-adjuvant chemotherapy had the poorest DFS (Table 4, Fig 4B).

**Overall survival.** For OS analysis 141 patients were available, 59 events occurred. The 2-year OS was 58% (median 2.4 years) (Fig 2C). Univariable Cox model didn't show association between the probabilities of poor survival and log OTT or log WT (Table 3). In the multivariable Cox-model chemotherapy schedule and disease stage remained significant; patients who only received neo-adjuvant chemotherapy or who had stage III disease had the poorest OS (Table 4, Fig 4C).

| Therapy response | LRC OR | P-value | DFS HR | P-value | OS HR | P-value |
|------------------|--------|---------|--------|---------|-------|---------|
| Log OTT          | 3.6    | 0.22    | 1.5    | 0.39    | 1.4   | 0.52    | 2.0 | 0.27 |
| Log WT           | 1.0    | 0.98    | 1.1    | 0.87    | 1.0   | 0.92    | 0.9 | 0.67 |

**Chemotherapy**

|                | LRC OR | P-value | DFS HR | P-value | OS HR | P-value |
|----------------|--------|---------|--------|---------|-------|---------|
| Concurrent     | 1.0    | 1.0     | 1.0    | 1.0     | 1.0   | 1.0     |
| Conc & neo-adj | 0.9    | 0.90    | 1.0    | 0.98    | 1.0   | 0.991   | 0.4 | 0.29 |
| Neo-adjuvant   | 6.4    | 0.01*   | 4.4    | 0.03*   | 3.0   | <0.01*  | 3.1 | 0.02* |
| None           | 6.1    | 0.03*   | 3.8    | 0.04*   | 2.5   | 0.07    | 2.4 | 0.19 |

**Tumor stage**

| Stage | LRC OR | P-value | DFS HR | P-value | OS HR | P-value |
|-------|--------|---------|--------|---------|-------|---------|
| IVb   | 1.0    | 1.0     | 1.0    | 1.0     | 1.0   | 1.0     |
| IVa   | 0.9    | 0.90    | 1.0    | 0.99    | 1.0   | 0.99    | 0.7 | 0.34 |
| III   | 1.0    | 0.98    | 1.0    | 0.90    | 0.9   | 0.68    | 0.5 | 0.02* |
| IIb   | 1.8    | 0.39    | 1.3    | 0.64    | 1.0   | 0.89    | 0.6 | 0.23 |
| IIa   | 0.6    | 0.72    | 0.5    | 0.59    | 0.4   | 0.36    | 0.3 | 0.31 |

OR = odds ratio; HR = hazard ratio; LRC = loco-regional control; DFS = disease free survival; OS = overall survival; OTT = overall radiation treatment time; WT = waiting time to radiotherapy

*significant outcome

1 = based on a cut-off point of 72 days

doi:10.1371/journal.pone.0151899.t004

Fig 2. Survival plots. (a) local regional control, (b) disease free survival and (c) overall survival. Above the x-axis is the number of patients at risk.

doi:10.1371/journal.pone.0151899.g002
The current study showed no correlation between overall treatment time and clinical outcome in patients with NPC. It was expected that a prolonged OTT was related to unfavourable clinical outcome, based on several studies that confirmed the benefit on tumour control and survival when radiotherapy for head and neck cancer was given without interruptions [13, 16–20]. Nevertheless, studies confirming this effects for NPC are limited [17, 21–23, 27]. Some studies focussed on the benefit of accelerated schedules of NPC, but also these results are conflicting [24, 25]. The current study analysed 142 patients with NPC only, all treated with curative intent for primary NPC. Therefore it was expected to be of great value for estimating the impact of an interrupted radiotherapy treatment in NPC. Besides, it could proof the focus for improving the clinical outcome of NPC patients.

Clinical outcome was defined in 4 parameters i.e.; treatment response, LRC, DFS and OS. This was based on experience from previous studies where we found difficulties completing follow up data [4, 30]. For every analysis, some patients had to be excluded due to uncertainty.

**Discussion**

The current study showed no correlation between overall treatment time and clinical outcome in patients with NPC. It was expected that a prolonged OTT was related to unfavourable clinical outcome, based on several studies that confirmed the benefit on tumour control and survival when radiotherapy for head and neck cancer was given without interruptions [13, 16–20]. Nevertheless, studies confirming this effects for NPC are limited [17, 21–23, 27]. Some studies focussed on the benefit of accelerated schedules of NPC, but also these results are conflicting [24, 25]. The current study analysed 142 patients with NPC only, all treated with curative intent for primary NPC. Therefore it was expected to be of great value for estimating the impact of an interrupted radiotherapy treatment in NPC. Besides, it could proof the focus for improving the clinical outcome of NPC patients.

Clinical outcome was defined in 4 parameters i.e.; treatment response, LRC, DFS and OS. This was based on experience from previous studies where we found difficulties completing follow up data [4, 30]. For every analysis, some patients had to be excluded due to uncertainty. Not only because of deviation in the follow up protocol, but also due to difficulties in estimating disease status. For therapy response, the combination of imaging studies and clinical follow
up was used. LRC was the preferable outcome parameter, because the given treatment was primarily a loco-regional treatment. Unfortunately, only 81 (57%) patients could be analysed for LRC, due to the lack of local-regional status data. DFS also includes patients who died without information about their disease stage. It is assumable that these patients died because of recurrent disease, therefore DFS was also a valuable outcome parameter. OS gave a good impression about the general prognosis for these patients. Except for one, all patients could be analysed for OS.

Unexpectedly, our results did not show an increased risk for poor clinical outcome when OTT was prolonged. Although all odds and hazard ratios were >1, no significance was reached. Based on these results it would be short-sighted to conclude that OTT does not affect therapy outcome for NPC. Studies that showed the increased risk on local failure in head and neck cancer when OTT was prolonged used a cut-off point between 7–8 weeks [21]. Also these cut-off points (49 days or 56 days) did not show significant increased risk (data not shown). This might be explained by the low number of patients who finished treatment within the recommended 7 weeks (n = 16). An explanation for not finding increased risk ratios in the continuous scale analysis might be that the effect of missing 2–4 weeks is not worse than missing 1–2 weeks. Another explanation could be that the OTT was overruled by other factors, and that the sample size was too small. As also concluded by others, larger, multi-institutional studies are needed to estimate the safe range OTT for NPC [27].

Another remarkable finding was that disease stage at diagnosis was not related to clinical outcome. The long waiting time can be an explanation. The negative effect of long WT is frequently described [31]. In the current study the median delay to initiation of radiation treatment was 4 months. The probability of an incomplete response, depending on waiting time, had the shape of a log-function (Fig 1). This means, in the first months it is of great importance to prevent delay, but at a certain time, the probability of poor outcome reaches a maximum despite a longer WT. Many patients received neo-adjuvant chemotherapy to overcome the waiting time. Nevertheless, disease progression and deterioration of the physical condition in this period is inevitable. The disease stage at diagnosis might not be representative for the actual stage that is treated. Some patients might have developed distant metastasis, which affects prognosis tremendously. In a currently on-going study we are evaluating the disease progression during the WT. Patients with a WT exceeding 3 months will be re-staged. Besides better insight in the actual disease stage, patients who develop stage IVc can be prevented from treatment that is deemed unsuccessful and has a high morbidity. Unnecessary use of the treatment units can be prevented, which will decrease WT for other patients. In that on-going study, also the physical deterioration during the WT will be analysed. A poor physical condition is frequently related to poor treatment outcome [18, 19].

Another shortcoming in disease stage are the methods used for confirming disseminated disease. Ultra sound, x-ray of the thorax and bone survey (x-ray of the bones) have low sensitivity for bone and lung metastasis. PET-scan was not available and bone scintigraphy is only used (and covered by insurance) in case of suspected bone lesions on the bone survey. Therefore, the presence of distant metastases might have been underestimated.

The group of patients that didn’t receive concurrent chemotherapy had significant worse clinical outcome. This factor remained significant for all outcome parameters in multivariable analysis. Also here careful interpretation is needed. Several other studies found the beneficial effect of concurrent chemo-radiotherapy above neo-adjuvant chemotherapy [32, 33]. Nevertheless, our results are probably biased by the choice of treatment. In general, patients who received concurrent chemotherapy are either ‘poor’ patients in a good condition after neo-adjuvant chemotherapy to overcome the waiting time, or ‘rich’ patients with a short waiting time who can start concurrent treatment immediately. The deterioration of the physical condition by neo-adjuvant treatment made concurrent chemotherapy too toxic for many patients.
While waiting for expanding the radiation facilities, other treatment modalities are needed to overcome the waiting time. These modalities should prevent progression, without deterioration of the patient’s condition and remain the possibility of concurrent chemo-radiotherapy, since concurrent chemo-radiotherapy treatment modality has been shown repeatedly as the most effective for advanced NPC [32].

The 2-year overall survival was 58%. When interpreting these statistics please note that patients who did not finish radiotherapy treatment were excluded from analysis, and therefore better than the rate reported in the introduction [4]. During the waiting time and during treatment patients died or dropped out, which would have had affected the overall survival negatively. The reason for excluding these patients in the current study was the different study aim.

In conclusion, although OTT and the WT are probably of influence on clinical outcome, this study showed the strongest effect for chemotherapy schedule. Every patient with advanced stage disease should get concurrent chemo-radiotherapy [33]. Only by reducing the waiting time, this can be accomplished. Therefore, radiation facilities should be expanded. However this is a time consuming process, and will not help to improve the life of cancer patients at short notice. While waiting for more units, more effectively use of the already available machines can be a step forward, like longer operational hours and better maintenance to prevent technical problems. Also, alternative (new) treatment modalities to overcome the waiting time, which prevent progression and avoid physical deterioration, might be helpful to remain the possibility to give concurrent chemotherapy.

Recently, problems have only increased. In the study period, the median waiting time for radiotherapy was 4 months. Due a change in the insurance system since January 2014, aiming to provide national health care insurance for all inhabitants of Indonesia, nowadays the waiting time for radiotherapy exceeds 1.5 year. Eighty-five per cent of the NPC patients are diagnosed in low-income countries, therefore Indonesia is not the only country who is struggling [1,5]. This is confirmed in a recently published article that showed the shortfall of radiotherapy capacity by country [34].

**Author Contributions**

Conceived and designed the experiments: SDS RF CH FJFR CRL MAW SRI IBT MT. Performed the experiments: SDS FJFR. Analyzed the data: SDS RF KS MKS AA MAW SRI IBT. Contributed reagents/materials/analysis tools: SDS RF CH SRD MAW SMH SRI IBT. Wrote the paper: SDS RF MAW KS MKS AA IBT.

**References**

1. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012.
2. Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol. 2012; 22(3):233–44. doi: 10.1016/j.semradonc.2012.03.008 PMID: 22687948
3. Wildeman MA, Fries R, Herdini C, Indrasari RS, Vincent AD, Tjokronagoro M, et al. Primary Treatment Results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia. PLoS One. 2013; 8(5): e63706. doi: 10.1371/journal.pone.0063706 PMID: 23675501
4. Lee AW. Global pattern of nasopharyngeal cancer in correlation to access to radiotherapy. NPC 2015 Yogyakarta, 7th International Nasopharyngeal Carcinoma Biannual Meeting Symposium. 2015.
5. Wei WI, Kwong DL. Current management strategy of nasopharyngeal carcinoma. Clin Exp Otorhinolaryngol. 2010; 3(1):1–12. doi: 10.3342/ceo.2010.3.1.1 PMID: 20379395
6. Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys. 2012; 82(1):327–33. doi: 10.1016/j.ijrobp.2010.09.011 PMID: 21035959
8. Song CH, Wu HG, Heo DS, Kim KH, Sung MW, Park CI. Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope. 2008; 118(4):663–70. doi: 10.1097/MLG.0b013e3181626c1e PMID: 18216741

9. Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer. 2003; 98(1):74–80. PMID: 12833458

10. Yang J, Yue JB, Liu J, Yu JM. Repopulation of tumor cells during fractionated radiotherapy and detection methods (Review). Oncol Lett. 2014; 7(6):1755–60. PMID: 24932228

11. Marks LB, Dewhirst M. Accelerated repopulation: friend or foe? Exploiting changes in tumor growth characteristics to improve the "efficiency" of radiotherapy. Int J Radiat Oncol Biol Phys. 1991; 21(5):1377–83. PMID: 1938539

12. Akimoto T, Mitsuhashi N, Hayakawa K, Sakurai H, Murata O, Ishizeki K, et al. Split-course accelerated hyperfractionation radiotherapy for advanced head and neck cancer: influence of split time and overall treatment time on local control. Jpn J Clin Oncol. 1997; 27(4):240–3. PMID: 9379511

13. Platek ME, McCloskey SA, Cruz M, Burke MS, Reid ME, Wilding GE, et al. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemoradiotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Head Neck. 2012.

14. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005; 5(7):516–25. PMID: 15965493

15. Fatema CN, Zhao S, Zhao Y, Murakami M, Yu W, Nishijima K, et al. Monitoring tumor proliferative response to radiotherapy using (18)F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67. Ann Nucl Med. 2013; 27(4):355–62. doi: 10.1007/s12149-013-0693-9 PMID: 23417197

16. Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, et al. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011; 81(5):e813–8. doi: 10.1016/j.ijrobp.2010.12.005 PMID: 21300455

17. Cannon DM, Geye HM, Hartig GK, Traynor AM, Hoang T, McCulloch TM, et al. Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemoradiotherapy. Head Neck. 2014; 36(8):1120–5. doi: 10.1002/hed.23419 PMID: 23804248

18. Rades D, Stoehr M, Kazic N, Hakim SG, Walz A, Schild SE, et al. Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70(4):1108–14. PMID: 17905528

19. McCloskey SA, Jaggiernauth W, Rigual NR, Hicks WL Jr, Popat SR, Sullivan M, et al. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemoradiotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009; 32(6):587–91. doi: 10.1097/COC.0b013e31819676d0 PMID: 19581794

20. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003; 362(9388):393–40. PMID: 14511925

21. Kwong DL, Sham JS, Chua DT, Choy DT, Au GK, Wu PM. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1997; 39(3):703–10. PMID: 936153

22. Lee AW, Chan DK, Fowler JF, Poon YY, Foo W, Law SC, et al. Effect of time, dose and fractionation on local control of nasopharyngeal carcinoma. Radiother Oncol. 1995; 36(1):24–31. PMID: 8525022

23. Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, et al. The effect of overall treatment time on local control in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy. Zhonghua Yi Xue Za Zhi. 2011; 91(7):469–72. PMID: 21418978

24. Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capецитабин, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015; 121(8):1328–38. doi: 10.1002/cncr.29208 PMID: 25529394

25. Pan ZQ, He XY, Guo XM, Ye M, Zhang Z, He SQ, et al. A phase III study of late course accelerated hyperfractionated radiotherapy versus conventionally fractionated radiotherapy in patients with nasopharyngeal carcinoma. Am J Clin Oncol. 2012; 35(6):600–5. doi: 10.1097/COC.0b013e318222df55 PMID: 22134512

26. Teo PM, Leung SF, Chan AT, Leung TW, Choi PH, Kwan WH, et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by
significant increase in neurologic complications. Int J Radiat Oncol Biol Phys. 2000; 48(5):1311–22. PMID: 11121628

27. Li PJ, Jin T, Luo DH, Shen T, Mai DM, Hu WH, Mo HY. Effect of prolonged radiotherapy treatment time on survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma. PLoS One. 2015; 10(10):e0141332. doi: 10.1371/journal.pone.0141332 PMID: 26506559

28. Stoker SD, Wildeman MA, Fles R, Indrasari SR, Hendini C, wildeman PL, et al. Prospective study: Current problems in radiotherapy for Nasopharyngeal Carcinoma in Yogyakarta, Indonesia. NPC conference 2013 Istanbul. 2013.

29. Wildeman MA, Zandbergen J, Vincent A, Herdini C, Middeldorp JM, Fles R, et al. Can an online clinical data management service help in improving data collection and data quality in a developing country setting? Trials. 2011; 12:190. doi: 10.1186/1745-6215-12-190 PMID: 21824421

30. Adham M, Stoker SD, Wildeman MA, Rachmadi L, Gondhowiardjo S, Atmakusumah D, et al. Current status of cancer care for young patients with nasopharyngeal carcinoma in Jakarta, Indonesia. PLoS One. 2014; 9(7):e102353. doi: 10.1371/journal.pone.0102353 PMID: 25019625

31. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol. 2008; 87(1):3–16. PMID: 18160158

32. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004; 22(22):4604–12. PMID: 15542811

33. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis Collaborative Group: www.thelancet.com/oncology Published online May 7, 2015. Lancet Oncol. 2015; 16(6):645–55. doi: 10.1016/S1470-2045(15)70126-9 PMID: 25957714

34. Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015 Sep; 16(10):1153–86. doi: 10.1016/S1470-2045(15)00222-3 PMID: 26419354